UCB INC
SpecialtyUCB INC is a specialty pharmaceutical company focused on Neurology, Immunology. Key products include FINTEPLA.
FDA Novel Drug Designations
(2016-2025)See 5 novel approvals →
UCB INC at a Glance
- Growing R&D activity with 30 trials in last 2 years
- Fast trial execution (24 months median completion)
UCB INC's Key Drugs
UCB INC's core commercial portfolio centers on BIMZELX, FINTEPLA, NAYZILAM, spanning Neurology and Immunology — its most strategically important drugs approved in the last 15 years.
UCB INC's Recent FDA Approvals
UCB INC secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
UCB INC's Therapeutic Areas
UCB INC's approved drugs and pipeline span 2 therapeutic areas, led by Neurology and Immunology, across 1 biologic and 10 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
UCB INC's Top Competitors
UCB INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
UCB INC Pipeline Snapshot
Active clinical trials for UCB INC across all therapeutic areas, from ClinicalTrials.gov.
Phase 3 Readout Calendar Pro
2 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 27/58 completed
- • Speed: 24 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges